Why is Foghorn Therapeutics stock plunging today?

Foghorn Therapeutics stock is plunging 31.2% in afternoon trading to reach $2.01, extending a brutal two-day sell-off that began after the company and Eli Lilly jointly announced they would not advance FHD-909 (LY4050784) into dose expansion following a Phase 1 dose escalation review that showed the SMARCA2/4 synthetic lethality biology did not translate into the level of clinical efficacy required to proceed. The two companies also elected not to advance a separate selective SMARCA2 degrader program, effectively ending all collaboration activities between them.

Today’s continued decline is being driven by a wave of analyst actions issued in response to the pipeline collapse. Wedbush cut its rating to Neutral from Outperform and slashed its price target to $2 from $10, with the firm noting the Lilly partnership had been a central pillar of its bullish thesis. BTIG separately downgraded the stock to Neutral from Buy. TD Cowen’s downgrade to Hold from Buy — issued the prior session — continued to weigh on sentiment, as did steep price target reductions from H.C. Wainwright (to $5 from $13), Guggenheim (to $5 from $12), and Stifel (to $5 from $12), while Citizens moved to Market Perform. The organizational restructuring, including a roughly 40% reduction in workforce, is expected to extend the company’s cash runway into the second half of 2029, but Foghorn’s pipeline is now entirely preclinical, raising questions about its near-term catalysts and whether it will need a new partner or additional capital to advance its EP300 degrader program toward the clinic.

The macro environment offered no cover for the stock. The S&P 500 gained +0.8%, the Dow Jones rose +0.5%, and the Nasdaq climbed +1.2% during today’s session, meaning FHTX’s sharp decline is entirely disconnected from broader market strength and reflects purely company-specific distress. Biotech peers in the chromatin regulation and oncology space were not subject to comparable negative news on the day.

Taken together, the failure of FHD-909 to demonstrate sufficient clinical efficacy, the complete termination of the Lilly collaboration, the loss of roughly 40% of the workforce, and a coordinated reassessment by multiple Wall Street analysts have combined to send the stock to a new multi-session low of $2.01, just modestly above its 52-week trough of $1.79, as investors reassess the company’s path forward as a fully preclinical-stage biotech.